- Featured Product
- KD/KO Validated
TGFBI / BIGH3 Polyclonal antibody
TGFBI / BIGH3 Polyclonal Antibody for FC, IF, IHC, IP, WB,ELISA
Cat no : 10188-1-AP
|Positive WB detected in||mouse eye tissue, HeLa cells, human kidney tissue, mouse liver tissue, Y79 cells|
|Positive IP detected in||HeLa cells|
|Positive IHC detected in||human kidney tissue, human liver cancer tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive IF detected in||HeLa cells|
|Positive FC detected in||HeLa cells|
|Western Blot (WB)||WB : 1:1000-1:4000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:200-1:1000 for WB|
|Immunohistochemistry (IHC)||IHC : 1:50-1:500|
|Immunofluorescence (IF)||IF : 1:50-1:500|
|Sample-dependent, check data in validation data gallery|
10188-1-AP targets TGFBI / BIGH3 in WB, Neutralization, IP, IHC, IF, FC,ELISA applications and shows reactivity with human, mouse, rat samples.
|Tested Reactivity||human, mouse, rat|
|Cited Reactivity||human, mouse, rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||TGFBI / BIGH3 fusion protein Ag0241|
|Full Name||transforming growth factor, beta-induced, 68kDa|
|Calculated molecular weight||683 aa, 75 kDa|
|Observed molecular weight||64 kDa|
|GenBank accession number||BC000097|
|Gene ID (NCBI)||7045|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
TGFBI, also named as BIGH3, Kerato-epithelin and RGD-CAP, binds to type I, II, and IV collagens. TGFBI is an adhesion protein which may play an important role in cell-collagen interactions. In cartilage, it may be involved in endochondral bone formation. TGFBI is an extracellular matrix adaptor protein, it has been reported to be differentially expressed in transformed tissues. TGFBI is a predictive factor of the response to chemotherapy, and suggest the use of TGFBI-derived peptides as possible therapeutic adjuvants for the enhancement of responses to chemotherapy.(PMID:20509890) Defects in TGFBI are the cause of epithelial basement membrane corneal dystrophy (EBMD). Defects in TGFBI are the cause of corneal dystrophy Groenouw type 1 (CDGG1). Defects in TGFBI are the cause of corneal dystrophy lattice type 1 (CDL1). Defects in TGFBI are a cause of corneal dystrophy Thiel-Behnke type (CDTB). Defects in TGFBI are the cause of Reis-Buecklers corneal dystrophy (CDRB). Defects in TGFBI are the cause of lattice corneal dystrophy type 3A (CDL3A). Defects in TGFBI are the cause of Avellino corneal dystrophy (ACD).
|Product Specific Protocols|
|WB protocol for TGFBI / BIGH3 antibody 10188-1-AP||Download protocol|
|IHC protocol for TGFBI / BIGH3 antibody 10188-1-AP||Download protocol|
|IF protocol for TGFBI / BIGH3 antibody 10188-1-AP||Download protocol|
|IP protocol for TGFBI / BIGH3 antibody 10188-1-AP||Download protocol|
|FC protocol for TGFBI / BIGH3 antibody 10188-1-AP||Download protocol|
|Click here to view our Standard Protocols|
Onco Targets Ther
Collagen stiffness promoted non-muscle-invasive bladder cancer progression to muscle-invasive bladder cancer.
Mol Ther Nucleic Acids
PPAR Gamma-Regulated MicroRNA 199a-5p Underlies Bone Marrow Adiposity in Aplastic Anemia.
Cancer Manag Res
Secreted TGF-beta-induced protein promotes aggressive progression in bladder cancer cells.
Identification and validation of TGFBI as a promising prognosis marker of clear cell renal cell carcinoma.
Int Med Case Rep J
Collagen fiber changes related to keratoconus with secondary corneal amyloidosis.
Cell Death Dis
Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (TGFBI) and tenascin C.